美股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

百济神州

231.99

-3.9500-1.67%

盘后：228.20-3.7900-1.63%17:17 EDT

成交量：37.57万

成交额：8,721.51万

市值：250.43亿

市盈率：-62.64

高：238.93

开：234.59

低：230.23

收：235.94

数据加载中...

总览公司新闻资讯公告

百济神州一季度亏损收窄，昊海生科实控人被立案，“减肥神药”司美格鲁肽Q1爆卖近80亿美元，德展健康涉合同纠纷诉讼

百济首次实现季度营业利润扭亏，泽布替尼销售额近57亿元

百济神州一季度亏损大幅收窄国内BTK抑制剂销售加速、PD-1销售减速

每日经济新闻

百济神州一季度产品收入近80亿元：跨越“创新鸿沟”，全球化突围成盈利胜负手

21世纪经济报道

年内股价涨幅超三成的百济神州，一季度营业利润扭亏为盈

异动解读 | 百济神州一季度业绩改善但盘前大跌5.25%，市场反应存疑

异动解读 | 百济神州股价盘前大跌5.25%，Q1财报亏损远超预期

百济神州第一季度净利亏损9450.3万元，同比大幅减亏

百济神州(688235.SH)一季度营业总收入80.48亿元，同比增长50.2%

百济神州首次实现季度GAAP盈利一季度泽布替尼全球销售额超50亿元

百济神州（06160）2025Q1强劲增长首次实现季度GAAP盈利

A股公告精选 | 百济神州(688235.SH)第一季度营业利润、利润总额由亏转盈

智通财经网

百济神州：第一季度净亏损9450.3万元

每日经济新闻

百济神州Q1营收增长50.2%至80.48亿元，百悦泽®全球销售额总计56.92亿

百济神州、宜联新药IND！礼来重金加注、AZ联合疗法新进展

医药经济报

【百济神州：2025年第一季度净亏损9450.3万元】百济神州公告，2025年第一季度实现营业总收入80.48亿元，同比增长50.2%；产品收入79.85亿元，同比增长49.9%；营业利润1.51亿元，去年同期为亏损18.3亿元；归属于母公司所有者的净利润亏损9450.3万元，去年同期亏损19.08亿元；产品收入增长主要得益于自研产品百悦泽®和百泽安®的销售增长。

百济神州：2025年第一季度净亏损9450.3万元

百济神州(06160)第一季度总收入11.17亿美元同比增加49%

【香港恒生指数收涨0.13% 恒生科技指数跌0.75%】香港恒生指数收涨0.13%，恒生科技指数跌0.75%。博雷顿上市首日涨超38%，弘业期货涨超34%；百济神州跌超7%，药明生物跌超6%，泡泡玛特跌超5%。

A股创新药概念午后持续下挫，百济神州跌近9%，荣昌生物、益方生物、一品红、信立泰、迪哲医药等多股跌超5%。

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/ONC/news?page=2"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ONC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ONC\",,,,,undefined,":{"symbol":"ONC","market":"US","secType":"STK","nameCN":"百济神州","latestPrice":231.99,"timestamp":1746820800000,"preClose":235.94,"halted":0,"volume":375689,"hourTrading":{"tag":"盘后","latestPrice":228.2,"preClose":231.99,"latestTime":"17:17 EDT","volume":56602,"amount":13129613.59,"timestamp":1746825449798},"delay":0,"floatShares":78845302,"shares":107947006,"eps":-3.70325,"marketStatus":"休市中","change":-3.95,"latestTime":"05-09 16:00:00 EDT","open":234.59,"high":238.93,"low":230.23,"amount":87215104.33812,"amplitude":0.036874,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.70325,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1747036800000},"marketStatusCode":7,"adr":0,"adrRate":13,"exchange":"NASDAQ","adjPreClose":235.94,"preHourTrading":{"tag":"盘前","latestPrice":232.7,"preClose":235.94,"latestTime":"09:02 EDT","volume":7106,"amount":1676581.96552,"timestamp":1746795722635},"postHourTrading":{"tag":"盘后","latestPrice":228.2,"preClose":231.99,"latestTime":"17:17 EDT","volume":56602,"amount":13129613.59,"timestamp":1746825449798},"volumeRatio":0.7560077917164717,"impliedVol":0.3961,"impliedVolPercentile":0.125},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ONC\",,,,,undefined,":{"symbol":"ONC","floatShares":78845302,"roa":"-3.22%","roe":"-11.44%","lyrEps":-6.124009,"volumeRatio":0.7560077917164717,"shares":107947006,"dividePrice":0,"high":238.93,"amplitude":0.036874,"preClose":235.94,"low":230.23,"week52Low":141.31,"pbRate":"7.16","psRate":"6.00","week52High":287.88,"institutionHeld":0,"latestPrice":231.99,"eps":-3.70325,"divideRate":0,"volume":375689,"delay":0,"ttmEps":-3.70325,"open":234.59,"prevYearClose":184.71,"prevWeekClose":255.77,"prevMonthClose":259.81,"prevQuarterClose":272.17,"fiveDayClose":255.77,"twentyDayClose":208.31,"sixtyDayClose":223.31},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ONC\",pageSize:20,pageCount:2,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2533960884","title":"百济神州一季度亏损收窄，昊海生科实控人被立案，“减肥神药”司美格鲁肽Q1爆卖近80亿美元，德展健康涉合同纠纷诉讼","url":"https://stock-news.laohu8.com/highlight/detail?id=2533960884","media":"谈医说药","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533960884?lang=zh_cn&edition=fundamental","pubTime":"2025-05-07 23:45","pubTimestamp":1746632754,"startTime":"0","endTime":"0","summary":"因公司原控股股东美林控股集团有限公司的关联方天宝嘉麟国际贸易有限公司与北京华新之间合同纠纷，北京华新向北京三中院提起诉讼。北京三中院裁定驳回北京华新的起诉。北京华新向北京高院提起上诉，请求依法撤销北京三中院的民事裁定书，并指令北京三中院对本案进行实体审理并作出公正判决及本案全部诉讼费用由被上诉人承担。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250508051033a475cdc3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250508051033a475cdc3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","06160","BK4139"],"gpt_icon":0},{"id":"2533303749","title":"百济首次实现季度营业利润扭亏，泽布替尼销售额近57亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2533303749","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533303749?lang=zh_cn&edition=fundamental","pubTime":"2025-05-07 22:50","pubTimestamp":1746629428,"startTime":"0","endTime":"0","summary":"2025年第一季度，百济神州实现营收80.48亿元，同比增长50.2%，其中产品收入79.85亿元，同比增长49.9%。根据A股业绩快报，百济神州实现营业利润、利润总额由亏损转为盈利，分别为1.51亿元、1.5亿元。目前，泽布替尼在全球75个市场获批，同时本季度在11个市场新增纳入或扩大报销范围。今年第一季度，泽布替尼全球销售额为56.92亿元，同比增长63.7%。百济神州称，泽布替尼本季度首次位居美国BTK抑制剂领域市场份额首位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250507225321a475803f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250507225321a475803f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","BK4139","688235"],"gpt_icon":0},{"id":"2533932462","title":"百济神州一季度亏损大幅收窄 国内BTK抑制剂销售加速、PD-1销售减速","url":"https://stock-news.laohu8.com/highlight/detail?id=2533932462","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533932462?lang=zh_cn&edition=fundamental","pubTime":"2025-05-07 22:41","pubTimestamp":1746628873,"startTime":"0","endTime":"0","summary":"作为国内创新药龙头企业，百济神州目前有3款主要自研产品，分别为BTK抑制剂泽布替尼、PD-1单抗替雷利珠单抗和PARP抑制剂帕米帕利。对于一季度的产品收入增长，公司归因于百悦泽、百泽安及安进授权产品的销售增长。具体来说，今年第一季度，百悦泽全球销售额总计56.92亿元，同比增长63.7%。而在竞争更为激烈的国内PD-1单抗市场中，百泽安实现销售额12.45亿元，同比增长19.3%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050722420597521340&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050722420597521340&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","PD","BK4139","BK4023","LU1169589451.USD","LU1169590202.USD","06160","688235"],"gpt_icon":0},{"id":"2533939776","title":"百济神州一季度产品收入近80亿元：跨越“创新鸿沟”，全球化突围成盈利胜负手","url":"https://stock-news.laohu8.com/highlight/detail?id=2533939776","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533939776?lang=zh_cn&edition=fundamental","pubTime":"2025-05-07 21:53","pubTimestamp":1746625980,"startTime":"0","endTime":"0","summary":"具体来看，业绩快报显示，百济神州实现营收80.48亿元，同比增长50.2%。基于此，百济神州预计2025年全年营业收入将介于人民币 352亿元至 381 亿元之间。目前，泽布替尼在全球75个市场获批，同时本季度在11个市场新增纳入或扩大报销范围。目前，该产品已在全球46个市场获批上市，超150万例患者接受治疗。在海外市场，百济神州在2024年10月初高调宣布，其PD-1抗癌药物替雷利珠单抗在获得FDA批准六个多月后，终于在美国正式上市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250507215548a4757443&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250507215548a4757443&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06160","ONC","BK4139","688235"],"gpt_icon":0},{"id":"2533936482","title":"年内股价涨幅超三成的百济神州，一季度营业利润扭亏为盈","url":"https://stock-news.laohu8.com/highlight/detail?id=2533936482","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533936482?lang=zh_cn&edition=fundamental","pubTime":"2025-05-07 21:40","pubTimestamp":1746625243,"startTime":"0","endTime":"0","summary":"今年以来，百济神州（ONC.NS、06160.HK、688235.SH）美股、港股、A股三地的股价累计涨幅均超过30%。5月7日晚间，百济神州公布的2025年第一季度美股业绩报告及A股业绩快报显示，公司业绩有继续向好趋势。百济神州A股业绩快报显示，2025年第一季度，公司实现营业利润、利润总额由亏损转为盈利，均实现盈利1.5亿元左右。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202505073398404544.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202505073398404544.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0307460666.USD","ONC","BK1500","BK4139","BK1161","BK1588","LU0588546209.SGD","LU2328871848.SGD","BK1583","LU1969619763.USD","06160"],"gpt_icon":0},{"id":"1155121510","title":"异动解读 | 百济神州一季度业绩改善但盘前大跌5.25%，市场反应存疑","url":"https://stock-news.laohu8.com/highlight/detail?id=1155121510","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1155121510?lang=zh_cn&edition=fundamental","pubTime":"2025-05-07 20:49","pubTimestamp":1746622160,"startTime":"0","endTime":"0","summary":"尽管百济神州发布的2025年第一季度财报显示业绩明显改善，但该公司股价今日盘前却大跌5.25%，引发市场关注。根据公司最新发布的财报，百济神州2025年第一季度实现营业总收入80.48亿元，同比增长50.2%；其中产品收入79.85亿元，同比增长49.9%。然而，尽管财务表现显著改善，百济神州股价在盘前交易中却出现大幅下跌。市场分析人士指出，创新药板块近期持续调整，可能对百济神州股价造成压力。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ONC"],"gpt_icon":0},{"id":"1161286799","title":"异动解读 | 百济神州股价盘前大跌5.25%，Q1财报亏损远超预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1161286799","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1161286799?lang=zh_cn&edition=fundamental","pubTime":"2025-05-07 20:48","pubTimestamp":1746622111,"startTime":"0","endTime":"0","summary":"5月7日盘前，生物科技公司百济神州股价大跌5.25%，引发市场关注。这一跌幅主要受到公司最新发布的2025年第一季度财报影响，财报显示公司仍未实现盈利，且亏损幅度超出市场预期。根据百济神州公布的2025年第一季度财报，公司实现营业总收入80.48亿元，同比增长50.2%；产品收入79.85亿元，同比增长49.9%。值得注意的是，创新药概念股近期整体表现疲软。这一行业整体走势也在一定程度上影响了百济神州的股价表现。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"异动解读 | 百济神州股价盘前大跌5.25%，Q1财报亏损远超预期","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ONC"],"gpt_icon":1},{"id":"2533809959","title":"百济神州第一季度净利亏损9450.3万元，同比大幅减亏","url":"https://stock-news.laohu8.com/highlight/detail?id=2533809959","media":"北京商报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533809959?lang=zh_cn&edition=fundamental","pubTime":"2025-05-07 20:33","pubTimestamp":1746621226,"startTime":"0","endTime":"0","summary":"北京商报讯（记者丁宁）5月7日晚间，百济神州（688235）发布2025年第一季度主要财务数据公告显示，报告期内，公司实现营业收入80.48亿元，同比增长50.2%；归属净利润为-9450.3万元，上年同期为-19.08亿元，同比大幅减亏。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202505073398350324.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202505073398350324.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["ONC","LU1969619763.USD","LU0588546209.SGD","BK1161","06160","BK1588","BK1583","LU2328871848.SGD","LU0307460666.USD","BK4139","BK1500"],"gpt_icon":0},{"id":"2533984281","title":"百济神州(688235.SH)一季度营业总收入80.48亿元，同比增长50.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2533984281","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533984281?lang=zh_cn&edition=fundamental","pubTime":"2025-05-07 20:02","pubTimestamp":1746619377,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百济神州(688235.SH)布2025年第一季度主要财务数据公告，报告期内，公司实现营业总收入80.48亿元，同比增长50.2%:其中产品收入79.85亿元，同比增长49.9%。营业利润、利润总额由亏损转为盈利。产品收入的增长主要得益于公司自研产品百悦泽®(泽布替尼胶囊),以及百泽安®(替雷利珠单抗)和安进授权产品的销售增长。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1290421.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2328871848.SGD","LU0307460666.USD","06160","ONC","BK0239","BK1161","BK1588","688235","LU0588546209.SGD","BK4139","LU1969619763.USD","BK1500","BK1583"],"gpt_icon":0},{"id":"2533905984","title":"百济神州首次实现季度GAAP盈利一季度泽布替尼全球销售额超50亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2533905984","media":"动脉网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533905984?lang=zh_cn&edition=fundamental","pubTime":"2025-05-07 19:47","pubTimestamp":1746618420,"startTime":"0","endTime":"0","summary":"百济神州在2025年第一季度实现首次GAAP季度盈利，营收达80.48亿元，同比增长50.2%。核心产品泽布替尼全球销售额突破56.92亿元，其中在美国市场销售额达到40.41亿元，同比增长61.9%，并成为美国CLL和BTK抑制剂市场的领导者。公司预计全年营业收入将介于352亿元至381亿元之间，并重申经营利润为正且经营活动产生现金流为正。此外，百济神州在全球六大洲的业务布局进一步加强，展示了其在肿瘤创新领域的强劲增长势头。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050719591394ef391b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050719591394ef391b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ONC"],"gpt_icon":0},{"id":"2533264981","title":"百济神州（06160）2025Q1强劲增长 首次实现季度GAAP盈利","url":"https://stock-news.laohu8.com/highlight/detail?id=2533264981","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533264981?lang=zh_cn&edition=fundamental","pubTime":"2025-05-07 19:43","pubTimestamp":1746618233,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，2025年5月7日，百济神州发布2025年第一季度美股业绩报告及A股业绩快报。业绩快报显示，百济神州实现营收80.48亿元，同比增长50.2%。财务表现方面，2025年第一季度，百济神州凭借全球收入的快速增长和经营费用的有效管理，在盈利方面再次取得重大进展。目前，该产品已在全球46个市场获批上市，超150万例患者接受治疗。同时，百济神州预计将于2025年下半年完成BGB-58067和BG-89894联合治疗临床试验的首例患者入组。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1290401.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688235","BK1500","BK1588","ONC","LU1969619763.USD","06160","LU2328871848.SGD","BK1583","LU0307460666.USD","BK4139","LU0588546209.SGD","BK1161"],"gpt_icon":0},{"id":"2533848699","title":"A股公告精选 | 百济神州(688235.SH)第一季度营业利润、利润总额由亏转盈","url":"https://stock-news.laohu8.com/highlight/detail?id=2533848699","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533848699?lang=zh_cn&edition=fundamental","pubTime":"2025-05-07 19:39","pubTimestamp":1746617962,"startTime":"0","endTime":"0","summary":"今日关注百济神州、源杰科技、纬德信息等公司公告。","market":"sg","thumbnail":"https://img.zhitongcaijing.com/image/20250507/20250507193933_19933.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20250507/20250507193933_19933.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1290396.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0239","LU0588546209.SGD","399300","LU1969619763.USD","06160","BK1500","LU2328871848.SGD","BK1583","BK1161","BK4139","LU0307460666.USD","ONC","BK1588","159982","688235"],"gpt_icon":0},{"id":"2533098132","title":"百济神州：第一季度净亏损9450.3万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2533098132","media":"每日经济新闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533098132?lang=zh_cn&edition=fundamental","pubTime":"2025-05-07 19:23","pubTimestamp":1746616993,"startTime":"0","endTime":"0","summary":"每经AI快讯，百济神州5月7日发布2025年第一季度主要财务数据公告，报告期内，公司实现营业总收入80.48亿元，同比增长50.2%；归属于母公司所有者的净利润为-9450.3万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202505073398303029.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202505073398303029.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["ONC","BK4139","BK1500","BK1588","LU0588546209.SGD","BK1583","LU0307460666.USD","LU2328871848.SGD","BK1161","LU1969619763.USD","06160"],"gpt_icon":0},{"id":"2533983707","title":"百济神州Q1营收增长50.2%至80.48亿元，百悦泽®全球销售额总计56.92亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2533983707","media":"财经网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533983707?lang=zh_cn&edition=fundamental","pubTime":"2025-05-07 19:05","pubTimestamp":1746615944,"startTime":"0","endTime":"0","summary":"5月7日，百济神州发布2025年一季报。披露公司Q1营收增长50.2%至80.48亿元，净亏损9450.3万元。2025年第一季度，百悦泽全球销售额总计56.92亿元，同比增长63.7%，在血液肿瘤领域进一步巩固领导地位。中国销售额总计5.90亿元，同比增长43.1%，主要得益于该产品在已获批适应症领域的销售增长。百悦泽临床开发项目迄今已在全球超过30个国家和地区开展超过35项试验，入组约7,100例患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050719061994ef2bc1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050719061994ef2bc1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","06160","688235"],"gpt_icon":0},{"id":"2533865329","title":"百济神州、宜联新药IND！礼来重金加注、AZ联合疗法新进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2533865329","media":"医药经济报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533865329?lang=zh_cn&edition=fundamental","pubTime":"2025-05-07 19:02","pubTimestamp":1746615770,"startTime":"0","endTime":"0","summary":"百济神州1类新药获批临床日前，CDE官网公示，百济神州申报的1类新药BGB-45035片就新适应症获得临床试验默示许可，拟开发治疗结节性痒疹。本次BGB-45035针对结节性痒疹新适应症获批临床，意味着该产品的临床开发迎来新的进展。此前，Alchemab宣布与礼来达成协议。值得一提的是，根据ECHO的结果，阿可替尼联合苯达莫司汀和利妥昔单抗疗法已于2025年1月17日获FDA批准用于MCL一线治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250507191622a475488d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250507191622a475488d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1267930730.SGD","LU0198837287.USD","LU0820561818.USD","LU2211815571.USD","LU2471134952.CNY","LU1868836591.USD","LU2264538146.SGD","LU2750360641.GBP","LU2237438978.USD","LU1093756325.SGD","IE00B2B36J28.USD","SG9999014880.SGD","LU2237443549.SGD","SG9999014914.USD","LU0106261372.USD","BK4187","LU2361044865.SGD","SGXZ99366536.SGD","GB00BDT5M118.USD","LU0640476718.USD","LU0882574139.USD","LU0266013472.USD","LU2237443978.SGD","LU0122379950.USD","LU1720051108.HKD","LU2237443382.USD","LU2602419157.SGD","LU2112291526.USD","IE00B1BXHZ80.USD","SG9999001176.SGD","LU0203201768.USD","LU2491050071.SGD","LU1720051017.SGD","BK4533","SG9999015978.USD","IE0004445239.USD","SG9999014906.USD","LU0354030438.USD","LU0471298777.SGD","ONC","06160","LU2552382215.SGD","LLY","SG9999001176.USD","AZ","LU1917777945.USD","688235","LU0289739699.SGD","LU2491050154.USD","IE00BFTCPJ56.SGD","IE00BK4W5L77.USD","LU1093756168.USD"],"gpt_icon":1},{"id":"2533998339","title":"【百济神州：2025年第一季度净亏损9450.3万元】百济神州公告，2025年第一季度实现营业总收入80.48亿元，同比增长50.2%；产品收入79.85亿元，同比增长49.9%；营业利润1.51亿元，去年同期为亏损18.3亿元；归属于母公司所有者的净利润亏损9450.3万元，去年同期亏损19.08亿元；产品收入增长主要得益于自研产品百悦泽®和百泽安®的销售增长。","url":"https://stock-news.laohu8.com/highlight/detail?id=2533998339","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533998339?lang=zh_cn&edition=fundamental","pubTime":"2025-05-07 18:57","pubTimestamp":1746615437,"startTime":"0","endTime":"0","summary":"百济神州公告，2025年第一季度实现营业总收入80.48亿元，同比增长50.2%；产品收入79.85亿元，同比增长49.9%；营业利润1.51亿元，去年同期为亏损18.3亿元；归属于母公司所有者的净利润亏损9450.3万元，去年同期亏损19.08亿元；产品收入增长主要得益于自研产品百悦泽®和百泽安®的销售增长。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/05/07185750201368.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["06160","ONC","688235"],"gpt_icon":0},{"id":"2533988218","title":"百济神州：2025年第一季度净亏损9450.3万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2533988218","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533988218?lang=zh_cn&edition=fundamental","pubTime":"2025-05-07 18:57","pubTimestamp":1746615436,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["ONC","LU0307460666.USD","BK4139","BK1583","BK0239","LU1969619763.USD","06160","688235","LU2328871848.SGD","BK1500","BK1161","BK1588","LU0588546209.SGD"],"gpt_icon":0},{"id":"2533904604","title":"百济神州(06160)第一季度总收入11.17亿美元 同比增加49%","url":"https://stock-news.laohu8.com/highlight/detail?id=2533904604","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533904604?lang=zh_cn&edition=fundamental","pubTime":"2025-05-07 18:10","pubTimestamp":1746612621,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百济神州 发布2025年第一季度业绩，该集团取得总收入11.17亿美元，同比增加49%;GAAP净利润127万美元，去年同期则亏损2.51亿美元;经调整净利润1.36亿美元，去年同期则取得亏损1.46亿美元; GAAP基本每股美国存托股份收益0.01美元。公告称，总收入的增长主要得益于百悦泽在美国和欧洲的销售额增长。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1290295.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2328871848.SGD","LU0307460666.USD","ONC","BK1500","LU0588546209.SGD","BK1588","BK4139","BK1583","BK0239","06160","LU1969619763.USD","688235","BK1161"],"gpt_icon":0},{"id":"2533673292","title":"【香港恒生指数收涨0.13% 恒生科技指数跌0.75%】香港恒生指数收涨0.13%，恒生科技指数跌0.75%。博雷顿上市首日涨超38%，弘业期货涨超34%；百济神州跌超7%，药明生物跌超6%，泡泡玛特跌超5%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2533673292","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533673292?lang=zh_cn&edition=fundamental","pubTime":"2025-05-07 16:10","pubTimestamp":1746605453,"startTime":"0","endTime":"0","summary":"香港恒生指数收涨0.13%，恒生科技指数跌0.75%。博雷顿上市首日涨超38%，弘业期货涨超34%；百济神州跌超7%，药明生物跌超6%，泡泡玛特跌超5%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"d308e1e0dcbd1f45bcee5ecd29af9255","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/05/07161050191141.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1147","LU0516423091.SGD","02833","LU0039217434.USD","LU0359202008.SGD","688235","BK1583","LU0348767384.USD","LU1880383366.USD","HHImain","LU1969619763.USD","LU1720050803.USD","HSTECH","LU0348735423.USD","LU2328871848.SGD","LU0359201612.USD","LU0856984785.SGD","LU0979878070.USD","LU1242518931.SGD","LU0348825331.USD","MCHmain","LU0819121731.USD","LU0456827905.SGD","HSI","BK1576","BK1564","BK1589","LU0140636845.USD","LU0516422440.USD","LU0572944931.SGD","LU2039709279.SGD","LU0326950275.SGD","IE00B0JY6N72.USD","LU0823426480.USD","LU0417516738.SGD","BK1161","LU0417516902.SGD","LU0307460666.USD","BK1592","02269","09992","513600","ONC","LU1242518857.USD","LU0516422366.SGD","06160","001236","BK1175","03678"],"gpt_icon":0},{"id":"2533623745","title":"A股创新药概念午后持续下挫，百济神州跌近9%，荣昌生物、益方生物、一品红、信立泰、迪哲医药等多股跌超5%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2533623745","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533623745?lang=zh_cn&edition=fundamental","pubTime":"2025-05-07 13:56","pubTimestamp":1746597395,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK1161","LU2328871848.SGD","BK0183","002294","BK1583","159992","BK4139","688192","06160","BK1500","BK0196","09995","BK0188","06978","LU1064130708.USD","LU2148510915.USD","688382","ONC","BK0187","LU1969619763.USD","688235","300723","BK0028","BK1588","399300","688331","BK1574","BK0239","LU1064131003.USD","LU0307460666.USD","159982","LU0588546209.SGD"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":2,"totalSize":200,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ONC\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-07","symbol":"ONC","fiscalQuarterEnding":"2025/03","expectedEps":-0.71,"name":null,"time":"盘前","type":"earning","dateTimestamp":1746590400000,"reportTimeType":"pre","actualEps":1.22},{"market":"US","date":"2025-02-27","symbol":"ONC","fiscalQuarterEnding":"2024/12","expectedEps":-0.88,"name":null,"time":"盘前","type":"earning","dateTimestamp":1740632400000,"reportTimeType":"pre","actualEps":-1.43},{"market":"US","date":"2024-11-12","symbol":"ONC","fiscalQuarterEnding":"2024/09","expectedEps":-0.88,"name":null,"time":"盘前","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"pre","actualEps":-1.15},{"market":"US","date":"2024-08-07","symbol":"ONC","fiscalQuarterEnding":"2024/06","expectedEps":-2.1,"name":null,"time":"盘前","type":"earning","dateTimestamp":1723003200000,"reportTimeType":"pre","actualEps":-1.15},{"market":"US","date":"2024-05-11","symbol":"ONC","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"盘后","type":"earning","dateTimestamp":1715400000000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ONC\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ONC\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2727,"buy":0.6818,"hold":0.0455,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6818,"analysts":22,"updateTime":1744084800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ONC\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ONC","date":"2025-05-09","current":-64.911375,"percent":0,"low":-64.911375,"twenty":-42.880619,"median":-38.484462,"eighty":-28.804303,"high":-22.805663,"avg":-36.524174,"sd":8.290813,"marketCap":25469016595},"quantilePoints":[{"date":"2025-01-03","current":-23.85925,"twenty":-23.85925,"median":-23.85925,"eighty":-23.85925,"marketCap":19590153584},{"date":"2025-01-10","current":-23.169003,"twenty":-23.588216,"median":-23.51181,"eighty":-23.096335,"marketCap":18938568040},{"date":"2025-01-17","current":-26.770744,"twenty":-26.217794,"median":-23.689854,"eighty":-23.142836,"marketCap":21882666138},{"date":"2025-01-24","current":-28.798988,"twenty":-27.60701,"median":-25.13119,"eighty":-23.374687,"marketCap":23683664763},{"date":"2025-01-31","current":-29.253094,"twenty":-28.895055,"median":-26.770744,"eighty":-23.516999,"marketCap":24179205805},{"date":"2025-02-07","current":-29.699946,"twenty":-29.114029,"median":-28.456686,"eighty":-23.723733,"marketCap":24422582437},{"date":"2025-02-14","current":-29.279798,"twenty":-29.132261,"median":-28.781271,"eighty":-23.9826,"marketCap":24061904635},{"date":"2025-02-21","current":-31.546239,"twenty":-29.269116,"median":-28.798062,"eighty":-24.917918,"marketCap":26058437677},{"date":"2025-02-28","current":-46.072488,"twenty":-30.312806,"median":-28.916244,"eighty":-26.238043,"marketCap":29706894943},{"date":"2025-03-07","current":-42.702936,"twenty":-33.205878,"median":-29.060335,"eighty":-26.487572,"marketCap":27534255325},{"date":"2025-03-14","current":-42.304107,"twenty":-40.627279,"median":-29.228112,"eighty":-26.926934,"marketCap":27277096074},{"date":"2025-03-21","current":-43.63686,"twenty":-41.989697,"median":-29.279798,"eighty":-27.60701,"marketCap":28136436571},{"date":"2025-03-28","current":-43.795471,"twenty":-42.273573,"median":-29.808923,"eighty":-28.393975,"marketCap":28238706493},{"date":"2025-04-04","current":-44.082326,"twenty":-43.290212,"median":-30.877376,"eighty":-28.597906,"marketCap":28423666794},{"date":"2025-04-11","current":-34.741183,"twenty":-42.946887,"median":-33.164233,"eighty":-28.695114,"marketCap":22400628140},{"date":"2025-04-17","current":-38.113584,"twenty":-42.748137,"median":-33.549429,"eighty":-28.784295,"marketCap":24575105056},{"date":"2025-04-25","current":-42.900785,"twenty":-42.748137,"median":-34.741183,"eighty":-28.796727,"marketCap":27661825682},{"date":"2025-05-02","current":-42.724352,"twenty":-42.75242,"median":-37.447221,"eighty":-28.798247,"marketCap":27548064220},{"date":"2025-05-09","current":-64.911375,"twenty":-42.880619,"median":-38.484462,"eighty":-28.804303,"marketCap":25469016595}],"updateTime":1747010853409}}}